TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

چکیده

To compare the efficacy and safety of brolucizumab 6 mg and aflibercept 2 mg in patients with neovascular age-related macular degeneration (nAMD) using an identical 4-week adjustment Treat-and-Extend regimen. Patients received brolucizumab (n = 366) or aflibercept (n = 368) at Weeks 0, 4, 8 and 16,…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط